Jazz Pharmaceuticals plc business relationships
Companies named in Jazz Pharmaceuticals plc’s 10-K filed 2026-02-24, and public companies whose annual reports name Jazz Pharmaceuticals plc. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 5.4 / 10
- AI naming
- 70 / 100 Top 1% in its category
- Agent readiness
- 5 / 100
- AI adoption
- 0 / 100
Named in Jazz Pharmaceuticals plc’s annual report 8
“As of December 31, 2025, five customers accounted for 81 % of gross accounts receivable, including ESSDS, which accounted for 41 % of gross accounts receivable, ASD, which accounted for 16 % of gross accounts receivable and McKesson, which accounted for 11 % of gross accounts receivable.” SEC filing
“Zepzelca, Rylaze, Ziihera and Vyxeos are sold to customers through subsidiary specialty distributors of McKesson, Cencora, and Cardinal.” SEC filing
“Defitelio is sold to hospital customers through subsidiary specialty distributors of McKesson.” SEC filing
“Rylaze is currently manufactured by Patheon, and the API of Rylaze is manufactured by AGC Biologics A/S.” SEC filing
“Under these amendments, we continue to have the right to a meaningful royalty from Hikma on net sales of the Hikma AG product throughout the extended Hikma AG period, which royalty rate was fixed through the end of 2025 and then subject to specified reductions as set forth in our agreement with Hikm...” SEC filing
“EU (licensed from Zymeworks) 3” SEC filing
“Within our oncology R&D program, in October 2022, we announced an exclusive licensing and collaboration agreement with Zymeworks providing us development and commercialization rights to Zymeworks' zanidatamab across all indications in the U.S., Europe, Japan and all other territories except for thos...” SEC filing
“Amended and Restated License Agreement, dated as of October 14, 2020, between Pharma Mar, S.A. and Jazz Pharmaceuticals Ireland Limited” SEC filing
Companies whose annual reports name Jazz Pharmaceuticals plc 6
“Settlement and License Agreement by and between Jazz Pharmaceuticals, Inc. and Jazz Pharmaceuticals Ireland Limited and Avadel CNS Pharmaceuticals, LLC and Flamel Ireland Limited.” SEC filing
“...ale Agreement, Zymeworks BC sold to the Subsidiary a 30 % interest in future royalties from the license agreements with Jazz Pharmaceuticals Ireland Limited ("Jazz") and BeOne Medicines Ltd. ("BeOne") relating to Ziihera (zanidatamab‑hrii), not to exceed 120 % of the maximum amount payable (excludin...” SEC filing
“...18, 2022, the Zymeworks BC entered into a License and Collaboration Agreement (the "Jazz Collaboration Agreement") with Jazz Pharmaceuticals Ireland Limited ("Jazz"), under which Jazz will have development and commercialization rights of zanidatamab throughout the world, but excluding the People's R...” SEC filing
“JZP898: IFNα INDUKINE Molecule Licensed Globally to Jazz Pharmaceuticals Ireland Limited” SEC filing
“Collaboration and License Agreement, dated as of April 6, 2022, by and between the Registrant and Jazz Pharmaceuticals Ireland Limited (incorporated by reference to Exhibit 10.1 to the Registrant's Quarterly Report on Form 10-Q, filed with the Securities and Exchange Commission on May 10, 2022, File...” SEC filing
“For example, in April 2022, we entered into a Collaboration and License Agreement, or the Collaboration Agreement, with Jazz Pharmaceuticals Ireland Limited, or Jazz, pursuant to which we granted Jazz certain licenses to develop and commercialize products containing our Interferon alpha, or IFNα, IN...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.